- Home
- INMB vs TNXP Comparison
INMB vs TNXP Comparison
Compare INMB & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- TNXP
- Stock Information
- Founded
- INMB 2015
- TNXP 2007
- Country
- INMB United States
- TNXP United States
- Employees
- INMB N/A
- TNXP N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- TNXP Health Care
- Exchange
- INMB Nasdaq
- TNXP Nasdaq
- Market Cap
- INMB 176.5M
- TNXP 207.5M
- IPO Year
- INMB 2019
- TNXP N/A
- Fundamental
- Price
- INMB $6.38
- TNXP $33.33
- Analyst Decision
- INMB Strong Buy
- TNXP Strong Buy
- Analyst Count
- INMB 3
- TNXP 2
- Target Price
- INMB $24.33
- TNXP $585.00
- AVG Volume (30 Days)
- INMB 627.1K
- TNXP 1.1M
- Earning Date
- INMB 07-31-2025
- TNXP 08-15-2025
- Dividend Yield
- INMB N/A
- TNXP N/A
- EPS Growth
- INMB N/A
- TNXP N/A
- EPS
- INMB N/A
- TNXP N/A
- Revenue
- INMB $50,000.00
- TNXP $10,041,000.00
- Revenue This Year
- INMB $82.14
- TNXP $11.66
- Revenue Next Year
- INMB $28,750.98
- TNXP $793.18
- P/E Ratio
- INMB N/A
- TNXP N/A
- Revenue Growth
- INMB N/A
- TNXP N/A
- 52 Week Low
- INMB $4.32
- TNXP $6.76
- 52 Week High
- INMB $10.50
- TNXP $137.25
- Technical
- Relative Strength Index (RSI)
- INMB 37.45
- TNXP 52.50
- Support Level
- INMB $6.68
- TNXP $33.41
- Resistance Level
- INMB $8.05
- TNXP $37.42
- Average True Range (ATR)
- INMB 0.62
- TNXP 3.48
- MACD
- INMB -0.10
- TNXP -1.12
- Stochastic Oscillator
- INMB 10.31
- TNXP 33.66
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.